Pembrolizumab Combination Improves PFS for First-Line MSI-High, dMMR Colorectal Cancer

Published by W Butcher on

The monoclonal antibody pembrolizumab (Keytruda; Merck) provides statistically significant improvements in progression-free survival relative to standard chemotherapy as first-line treatment in patients with microsatellite-instability high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer, new research has concluded. 

Read More…

Categories: Uncategorized

0 Comments

Leave a Reply

Avatar placeholder

Your email address will not be published.